Medicare Coverage Of Tumor Assays Should Be Monitored - MCAC Panel
This article was originally published in The Gray Sheet
Executive Summary
Human tumor assay systems demonstrate clinical utility for certain patients and hold promise as a tool for treating a broad range of cancers, the Laboratory and Diagnostic Services Panel of the Medicare Coverage Advisory Committee agreed at its Nov. 15-16 meeting in Baltimore.